TI
IBRX icon

Trexquant Investment’s ImmunityBio IBRX Stock Holding History

Trexquant Investment’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.1M Buy
+696,547
New +$5.27M 0.04% 644
2017
Q1 		– Sell
-36,593
Closed -$209K – 1186
2016
Q4 		$209K Buy
+36,593
New +$244K 0.03% 801

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Trexquant Investment's IBRX Position: Q2 2026 in Review

Trexquant Investment opened a new position in ImmunityBio (IBRX) in Q2 2026: 696,547 shares worth $6.1M. The stake represents 0.04% of the portfolio and ranks #644 among its holdings. This is a return to the name: Trexquant Investment previously reported a position in IBRX as recently as Q4 2016.

Trexquant Investment first reported a position in IBRX in Q4 2016 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Trexquant Investment held 696,547 shares of ImmunityBio worth $6.1M as of Q2 2026.
  • ImmunityBio was a new Trexquant Investment position in Q2 2026.
  • ImmunityBio made up 0.04% of Trexquant Investment's portfolio in Q2 2026, its #644 holding.
  • Trexquant Investment first reported a position in ImmunityBio in Q4 2016 and has held it in 2 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.